AURKA and hepatocellular carcinoma: In addition, combination of PHA-739358 with sorafenib resulted in an additive effect on tumor growth inhibition [150], thus highlighting that inhibition of AURKA, either alone, or in combination with sorafenib, may be a promising therapeutic approach for HCC.